Phosphodiesterase 5/protein kinase G signal governs stemness of prostate cancer stem cells through Hippo pathway

Li, 2008, PC3 human prostate carcinoma cell holoclones contain self-renewing tumor-initiating cells, Cancer Res, 68, 1820, 10.1158/0008-5472.CAN-07-5878 Zhang, 2010, PC3 prostate tumor-initiating cells with molecular profile FAM65Bhigh/MFI2low/LEF1low increase tumor angiogenesis, Mol. Cancer, 9, 319, 10.1186/1476-4598-9-319 De Marzo, 1998, Stem cell features of benign and malignant prostate epithelial cells, J. Urol, 160, 2381, 10.1016/S0022-5347(01)62196-7 Shen, 2010, Molecular genetics of prostate cancer: new prospects for old challenges, Genes Dev, 24, 1967, 10.1101/gad.1965810 Liu, 2011, The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44, Nat. Med, 17, 211, 10.1038/nm.2284 Zhao, 2010, Hippo signaling at a glance, J. Cell Sci, 123, 4001, 10.1242/jcs.069070 Piccolo, 2014, The biology of YAP/TAZ: hippo signaling and beyond, Physiol. Rev, 94, 1287, 10.1152/physrev.00005.2014 Dong, 2007, Elucidation of a universal size-control mechanism in Drosophila and mammals, Cell, 130, 1120, 10.1016/j.cell.2007.07.019 Lei, 2008, TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway, Mol. Cell. Biol, 28, 2426, 10.1128/MCB.01874-07 Kim, 2015, Transcriptional co-repressor function of the hippo pathway transducers YAP and TAZ, Cell Rep, 11, 270, 10.1016/j.celrep.2015.03.015 Zhao, 2011, The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal, Nat. Cell Biol, 13, 877, 10.1038/ncb2303 Cordenonsi, 2011, The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells, Cell, 147, 759, 10.1016/j.cell.2011.09.048 Hayashi, 2015, An imbalance in TAZ and YAP expression in hepatocellular carcinoma confers cancer stem cell-like behaviors contributing to disease progression, Cancer Res, 75, 4985, 10.1158/0008-5472.CAN-15-0291 Nguyen, 2015, ERG activates the YAP1 transcriptional program and induces the development of age-related prostate tumors, Cancer Cell, 27, 797, 10.1016/j.ccell.2015.05.005 Zhang, 2015, The hippo pathway effector YAP regulates motility, invasion, and castration-resistant growth of prostate cancer cells, Mol. Cell. Biol, 35, 1350, 10.1128/MCB.00102-15 Butt, 1994, cAMP- and cGMP-dependent protein kinase phosphorylation sites of the focal adhesion vasodilator-stimulated phosphoprotein (VASP) in vitro and in intact human platelets, J. Biol. Chem, 269, 14509, 10.1016/S0021-9258(17)36652-8 Gong, 2014, Inhibition of phosphodiesterase 5 reduces bone mass by suppression of canonical Wnt signaling, Cell Death Dis, 5, 10.1038/cddis.2014.510 Marsh, 2000, A short history of nitroglycerine and nitric oxide in pharmacology and physiology, Clin. Exp. Pharmacol. Physiol, 27, 313, 10.1046/j.1440-1681.2000.03240.x Vasquez, 2015, Novel Therapeutic Targets for Phosphodiesterase 5 Inhibitors: current state-of-the-art on systemic arterial hypertension and atherosclerosis, Curr. Pharm. Biotechnol, 17 Krumenacker, 2006, Differential expression of genes involved in cGMP-dependent nitric oxide signaling in murine embryonic stem (ES) cells and ES cell-derived cardiomyocytes, Nitric Oxide, 14, 1, 10.1016/j.niox.2005.06.010 D'Atri, 2009, Nitric oxide: news from stem cells to platelets, Curr. Med. Chem, 16, 417, 10.2174/092986709787315513 Ybarra, 2011, Involvement of the nitric oxide-soluble guanylyl cyclase pathway in the oxytocin-mediated differentiation of porcine bone marrow stem cells into cardiomyocytes, Nitric Oxide, 24, 25, 10.1016/j.niox.2010.09.008 Hoke, 2012, Preconditioning by phosphodiesterase-5 inhibition improves therapeutic efficacy of adipose-derived stem cells following myocardial infarction in mice, Stem Cells, 30, 326, 10.1002/stem.789 Barone, 2015, Expression and function of phosphodiesterase type 5 in human breast cancer cell lines and tissues: implications for targeted therapy, Clin. Cancer Res Li, 2015, Suppression of β-catenin/TCF transcriptional activity and colon tumor cell growth by dual inhibition of PDE5 and 10, Oncotarget, 6, 27403, 10.18632/oncotarget.4741 Karami-Tehrani, 2012, Evaluation of PDE5 and PDE9 expression in benign and malignant breast tumors, Arch. Med. Res, 43, 470, 10.1016/j.arcmed.2012.08.006 Shi, 2011, Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance, Cancer Res, 71, 3029, 10.1158/0008-5472.CAN-10-3820 Roberts, 2014, PDE5 inhibitors enhance the lethality of standard of care chemotherapy in pediatric CNS tumor cells, Cancer Biol. Ther, 15, 758, 10.4161/cbt.28553 Chen, 2012, Ascorbic acid uptaken by sodium-dependent vitamin C transporter 2 induces βhCG expression through Sp1 and TFAP2A transcription factors in human choriocarcinoma cells, J. Clin. Endocrinol. Metab, 97, 1667, 10.1210/jc.2012-1753 Niyazi, 2007, Counting colonies of clonogenic assays by using densitometric software, Radiat. Oncol, 2, 4, 10.1186/1748-717X-2-4 Henrique, 2005, Frequent 14-3-3 sigma promoter methylation in benign and malignant prostate lesions, DNA Cell Biol, 24, 264, 10.1089/dna.2005.24.264 Li, 2015, The Hippo transducer TAZ promotes epithelial to mesenchymal transition and cancer stem cell maintenance in oral cancer, Mol. Oncol, 9, 1091, 10.1016/j.molonc.2015.01.007 Fujimoto, 2015, PAR1 participates in the ability of multidrug resistance and tumorigenesis by controlling Hippo-YAP pathway, Oncotarget, 6, 34788, 10.18632/oncotarget.5858 Madhusoodanan, 2007, NO-cGMP signaling and regenerative medicine involving stem cells, Neurochem. Res, 32, 681, 10.1007/s11064-006-9167-y Jeon, 2005, MPhosphodiesterase: overview of protein structures, potential therapeutic applications and recent progress in drug development, Cell. Mol. Life Sci, 62, 1198, 10.1007/s00018-005-4533-5 Mujoo, 2008, Role of nitric oxide signaling components in differentiation of embryonic stem cells into myocardial cells, Proc. Natl. Acad. Sci. U.S.A., 105, 18924, 10.1073/pnas.0810230105 Firger, 2015, Nitric oxide inhibitors hit target for triple-negative breast cancer, J. Natl. Cancer Inst, 107, 10.1093/jnci/djv235 Puglisi, 2015, High nitric oxide production, secondary to inducible nitric oxide synthase expression, is essential for regulation of the tumour-initiating properties of colon cancer stem cells, J. Pathol, 236, 479, 10.1002/path.4545 Basu, 2003, Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis, Mol. Cell, 11, 11, 10.1016/S1097-2765(02)00776-1 Zhou, 2009, Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene, Cancer Cell, 16, 425, 10.1016/j.ccr.2009.09.026 Schlegelmilch, 2011, Yap1 acts downstream of alpha-catenin to control epidermal proliferation, Cell, 144, 782, 10.1016/j.cell.2011.02.031 Sorrentino, 2014, Metabolic control of YAP and TAZ by the mevalonate pathway, Nat. Cell Biol, 16, 357, 10.1038/ncb2936 Sarfati, 2003, Sildenafil and vardenafil, types 5 and 6 phosphodiesterase inhibitors, induce caspase-dependent apoptosis of B-chronic lymphocytic leukemia cells, Blood, 101, 265, 10.1182/blood-2002-01-0075 Zhu, 2005, Suppression of cyclic GMP-specific phosphodiesterase 5 promotes apoptosis and inhibits growth in HT29 cells, J. Cell. Biochem, 94, 336, 10.1002/jcb.20286 Wang, 2015, Transcriptional co-activator TAZ sustains proliferation and tumorigenicity of neuroblastoma by targeting CTGF and PDGF-beta, Oncotarget, 6, 9517, 10.18632/oncotarget.3367 Xiao, 2015, TAZ regulates cell proliferation and epithelial-mesenchymal transition of human hepatocellular carcinoma, Cancer Sci, 106, 151, 10.1111/cas.12587 Liu, 2002, Specific cGMP binding by the cGMP binding domains of cGMP-binding cGMP specific phosphodiesterase, Cell. Signal, 14, 45, 10.1016/S0898-6568(01)00216-9 Lim, 2003, Exisulind and related compounds inhibit expression and function of the androgen receptor in human prostate cancer cells, Clin. Cancer Res, 9, 4972 Lim, 1999, Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines, Biochem. Pharmacol, 58, 1097, 10.1016/S0006-2952(99)00200-2 Goluboff, 1999, Exisulind (sulindac sulfone) suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing apoptosis, Urology, 53, 440, 10.1016/S0090-4295(98)00513-5 Narayanan, 2007, Exisulind in combination with celecoxib modulates epidermal growth factor receptor, cyclooxygenase-2, and cyclin D1 against prostate carcinogenesis: in vivo evidence, Clin. Cancer Res, 13, 5965, 10.1158/1078-0432.CCR-07-0744 Booth, 2015, PDE5 inhibitors enhance celecoxib killing in multiple tumor types, J. Cell. Physiol, 230, 1115, 10.1002/jcp.24843